Inhibikase Therapeutics Stock News

BOSTON and ATLANTA , Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics t

IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients No clinicall

BOSTON and ATLANTA , Sept. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET CompanyParticipants Milton Werner - CEO Joseph Frattaroli - CFO Alex Lobo - Stern IR Conference

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Milton Werner - Chief Executive Officer J

BOSTON and ATLANTA , May 10, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Par

Inhibikase Therapeutics, Inc. (IKT) CEO Dr. Milton Werner on Q4 2021 Results - Earnings Call Transcript

BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Par

BOSTON and ATLANTA, March 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Park

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

Inhibikase Therapeutics Inc (IKT) shares closed 2.0% lower than its previous 52 week low, giving the company a market cap of $40M. The stock is currently down 76.8% year-to-date, down 83.7% over the past 12 months, and down 83.8% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 19.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 158.4% The company's stock price performance over the past 12 months lags the peer average by 167.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of recent ratings and price targets for Inhibikase Therapeutics []

Inhibikase Therapeutics (NYSE: IKT) is one of 237 publicly-traded companies in the Biological products, except diagnostic industry, but how does it compare to its rivals? We will compare Inhibikase Therapeutics to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership. Valuation & Earnings This table compares []

In last trading session, Inhibikase Therapeutics Inc. (NASDAQ:IKT) saw 0.55 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $1.65 trading at -$0.12 or -6.78% at ring of the bell on the day assigns it a market valuation of $41.25M. That closing price of IKTs stock is Inhibikase Therapeutics Inc. (NASDAQ:IKT) Has Recovered -2.42% So Far, But Another -627.27% Loss Cannot Be Ruled Out Read More »

The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) increased by over 10% pre-market today. This is why it happened.